EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Inflammatory bowel diseases (*DIIS) therapies biologics for the management of crohn’s disease and *ulcerative colitis

Júlio Elias Calheiros, Beatriz de Luna Costa Pinheiro, Mauricio Martinez Puglia, Anderson Paulo de Oliveira, Ana Luiza Zampar Quintana Gomes, Aline Cristina Couto da Silva, Délio Tiago Martins Malaquias, Érica Miriam Fernandes M. Vao, Leonardo Tomé da Silva, Victor Rodrigues de Paula, Wellington da Silva Pereira da Cunha, José Carlos Ferreira da Silva und 10 weitere

Journal of Digestive and Liver Diseases · 05.05.2025 · 11 (1)

DOI: 10.52338/jodld.2025.4714 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Digestive and Liver Diseases, online erschienen am 05.05.2025. Verfasst von Júlio Elias Calheiros und 21 weiteren Autor:innen. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inflammatory bowel diseases (IBDs), including Crohn’s disease (CD) and ulcerative colitis (UC), are chronic diseases of the gastrointestinal tract characterized by recurrent inflammation, significant functional impact and impaired quality of life. The treatment of these diseases has undergone important advances in recent decades, especially with the introduction of biological therapies. This study aimed to carry out a systematic review of the literature on the efficacy and safety of biological therapies in the management of CD and CRU. The search was carried out in the PubMed, SciELO, LILACS, Embase and Web of Science databases, resulting in the inclusion of 37 studies published between 2013 and 2024. The results showed that anti-TNF agents (infliximab, adalimumab, among others) are the most widely used and widely studied, with consolidated efficacy in inducing and maintaining remission. However, therapeutic failures associated with immunogenicity are common. Vedolizumab and ustekinumab have emerged as effective options with a favorable safety profile. JAK inhibitors, such as tofacitinib, have shown good results in CR, although they require greater vigilance due to potential adverse effects. The discussion highlighted the importance of a personalized approach, guided by treat-to-target strategies and the use of biomarkers. It is concluded that biological therapies have revolutionized the treatment of IBD, but the appropriate choice requires careful clinical evaluation, continuous monitoring and equitable access to technologies.

Zitieren

APA

Calheiros, J. E., Pinheiro, B. D. L. C., Puglia, M. M., Oliveira, A. P. D., Gomes, A. L. Z. Q., Silva, A. C. C. D., Malaquias, D. T. M., Vao, É. M. F. M., Silva, L. T. D., Paula, V. R. D., Cunha, W. D. S. P. D., Silva, J. C. F. D., Carvalho, G. U., Yamashiro, G. C., Ervilha, A. L. N., Moretti, V. C. G., Leitão, B., Oliveira, G. B. L. D., Tudela, R. R., …, & Bezerra, T. A. R. (2025). Inflammatory bowel diseases (*DIIS) therapies biologics for the management of crohn’s disease and *ulcerative colitis. Journal of Digestive and Liver Diseases, 11(1). https://doi.org/10.52338/jodld.2025.4714

Vancouver

Calheiros JE, Pinheiro BDLC, Puglia MM, Oliveira APD, Gomes ALZQ, Silva ACCD, et al. Inflammatory bowel diseases (*DIIS) therapies biologics for the management of crohn’s disease and *ulcerative colitis. Journal of Digestive and Liver Diseases. 2025;11(1). doi:10.52338/jodld.2025.4714

BibTeX
@article{Calheiros2025,
  author = {Calheiros, Júlio Elias and Pinheiro, Beatriz de Luna Costa and Puglia, Mauricio Martinez and Oliveira, Anderson Paulo de and Gomes, Ana Luiza Zampar Quintana and Silva, Aline Cristina Couto da and Malaquias, Délio Tiago Martins and Vao, Érica Miriam Fernandes M. and Silva, Leonardo Tomé da and Paula, Victor Rodrigues de and Cunha, Wellington da Silva Pereira da and Silva, José Carlos Ferreira da and Carvalho, Gabriel Urquiza and Yamashiro, Giovana Casarini and Ervilha, Ana Laura Nogueira and Moretti, Victoria Cristina Galbes and Leitão, Bárbara and Oliveira, Giovana Barreto Lima de and Tudela, Rubens Rodrigues and Alvarenga, Cristiano Bento and Junior, Joel Eloi Belo and Bezerra, Thiago Augusto Rochetti},
  title = {Inflammatory bowel diseases (*DIIS) therapies biologics for the management of crohn’s disease and *ulcerative colitis},
  journal = {Journal of Digestive and Liver Diseases},
  year = {2025},
  volume = {11},
  number = {1},
  doi = {10.52338/jodld.2025.4714}
}
Kostenlos starten →